Randomized trial · people
Tesamorelin: 10.9% less visceral fat at 6 months in HIV patients
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In people with HIV and excess belly fat, tesamorelin reduced deep belly fat while it was taken, and the effect faded quickly after it was stopped.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 404
- Published
- 2010
- Journal
- J Acquir Immune Defic Syndr
What they tested
The team tested whether daily tesamorelin reduces deep belly fat in people with HIV on antiretroviral therapy who carry excess abdominal fat.
How the study was done
A double-blind, randomized, placebo-controlled trial in 404 people with HIV and excess abdominal fat. For the first 6 months they got 2 mg tesamorelin under the skin daily or placebo (a dummy shot) in a 2:1 ratio; then, for months 6 to 12, the tesamorelin group was randomized again to keep taking it or switch to placebo, and the placebo group switched to tesamorelin.

What they found
At 6 months, visceral fat (the deep fat around the organs) fell by 10.9% (21 cm2) on tesamorelin vs 0.6% (1 cm2) on placebo. Trunk fat, waist size and waist-hip ratio also improved, while fat under the skin of the belly and limbs did not change. IGF-1, a growth-related hormone, went up with no change in blood sugar measures, and both patients' distress about belly appearance and doctors' ratings of belly profile improved. Those who stayed on tesamorelin for 12 months had about 18% less visceral fat, but people who switched to placebo after 6 months quickly lost their early gains.
What it doesn’t show
The trial only included people with HIV on antiretroviral therapy who had excess belly fat, so it does not show effects in other groups. It ran 12 months, and the benefit faded fast after stopping, so it does not show lasting effects off the drug.
The paper
Falutz et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010.
The compound
More studies on Tesamorelin
- Tesamorelin: visceral fat down 27.71 cm² in HIV lipodystrophyMeta-analysis · people · 2026
- Tesamorelin shifted liver gene activity in HIV-related fatty liverRandomized trial · people · 2020
- Tesamorelin: denser, larger trunk muscles at 26 weeks in HIVRandomized trial · people · 2019
- Tesamorelin: no change in glucose control in type 2 diabetesRandomized trial · people · 2017
- Tesamorelin cut visceral and liver fat over 6 months in HIV patientsRandomized trial · people · 2014
- Tesamorelin had little effect on simvastatin and ritonavir levelsRandomized trial · people · 2013
- Every study on Tesamorelin
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.